

Opiate Dependence Agents

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS – Maximum Days’ Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have ‘X’ DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**
 AmeriHealth Caritas Louisiana **1-800-684-5502**
 Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**
 Healthy Blue **1-844-521-6942**
 Louisiana Healthcare Connections **1-888-929-3790**
 UnitedHealthcare **1-800-310-6826**

Opiate Dependence Agents

POS Edits		
AL – The agents listed in the table to the right are limited to use in recipients who meet specific age requirements.	Minimum Age Requirements	
	Generic (Brand Example)	Minimum Age
	Buprenorphine (Sublocade®)	18 years
	Buprenorphine SL	16 years
	Buprenorphine/Naloxone (Suboxone®, Zubsolv®)	16 years
	Lofexidine (Lucemyra®)	18 years
	Naltrexone Extended-Release Injectable Suspension (Vivitrol®)	18 years
	Naltrexone Tablet	18 years
CU – These agents are monitored at POS for concurrent use with other agents. <ul style="list-style-type: none"> - Incoming pharmacy claims for a buprenorphine-containing agent used for opiate dependence will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for an opioid analgesic. 		
DD – Pharmacy claims for naltrexone tablets or naltrexone extended-release injectable suspension (Vivitrol®) will deny for drug-drug interaction when the recipient has an active prescription (a prescription in which the days' supply has not expired) for any opioid (including buprenorphine-containing products) and vice versa.		
DS – Pharmacy claims for lofexidine tablets are limited to a 14-day supply per 6-month period.		
DX – Pharmacy claims for some agents must be submitted with an appropriate diagnosis code. <ul style="list-style-type: none"> - Pharmacy claims for all buprenorphine opiate dependence agents (single-ingredient and combination) must be submitted with a diagnosis code for opioid dependence (F11.2*). - Pharmacy claims for lofexidine (Lucemyra®) must be submitted with a diagnosis code for ONE of the following: <ul style="list-style-type: none"> o Opioid abuse with withdrawal – F11.13 o Opioid dependence with withdrawal – F11.23 o Opioid use, unspecified with withdrawal – F11.93 - Pharmacy claims for naltrexone tablets or naltrexone extended-release injectable suspension (Vivitrol®) must be submitted with either a diagnosis code for opioid dependence (F11.2*) or alcohol dependence (F10.2*). <p><i>* Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code</i></p>		
MD – The following agents are limited to a maximum daily dose: <ul style="list-style-type: none"> - Buprenorphine agents (single-ingredient and combination) are limited to a maximum daily dose of 24mg per day of buprenorphine or buprenorphine equivalent. Refer to specific product prescribing information for buprenorphine equivalence charts. - Lofexidine 0.18mg tablet is limited to a maximum daily dose of 2.88mg (16 tablets). 		

Opiate Dependence Agents

POS Edits		
QL – Some agents have quantity limits as listed in the chart to the right.	Quantity Limits	
	Generic (Brand Example)	Quantity Limit
	Buprenorphine Extended-Release Injection (Sublocade®)	1 unit/26 days
	Buprenorphine SL Tablet 2mg	2 units/day
	Buprenorphine SL Tablet 8mg	3 units/day
	Buprenorphine/Naloxone 2mg/0.5mg SL Tab (Suboxone®)	2 units/day
	Buprenorphine/Naloxone 2mg/0.5mg SL Film (Suboxone®)	1 unit/day
	Buprenorphine/Naloxone 4mg/1mg SL Film (Suboxone®)	1 unit/day
	Buprenorphine/Naloxone 8mg/2mg SL Film/Tab (Suboxone®)	3 units/day
	Buprenorphine/Naloxone 12mg/3mg SL Film (Suboxone®)	2 units/day
	Buprenorphine/Naloxone SL Tablet 0.7mg/0.18mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 1.4mg/0.36mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 2.9mg/0.71mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 5.7mg/1.4mg (Zubsolv®)	3 units/day
	Buprenorphine/Naloxone SL Tablet 8.6mg/2.1mg (Zubsolv®)	2 units/day
	Buprenorphine/Naloxone SL Tablet 11.4mg/2.9mg (Zubsolv®)	1 unit/day
	Naltrexone Extended-Release Injectable Suspension (Vivitrol®)	1 unit/28 days
	Naloxone Nasal Spray (Narcan®)	2 units/90 days
	Naloxone Nasal Spray (Kloxxado™)	2 units/90 days
	Naloxone Injectable Solution/Cartridge 0.4mg/ml	2 units/90 days
	Naloxone Injectable Solution Syringe 1mg/ml	2 units/90 days
	Naloxone Injectable Solution (5ml, 10ml, 20ml) 1mg/ml	1 unit/90 days
	Naloxone Injectable Solution (10ml) 0.4mg/ml	1 unit/90 days
	Naloxone Injectable Solution (Zimhi™)	2 syringes (1ml)/90 days
TD – These agents are monitored at the pharmacy POS for duplication of therapy with each other. <ul style="list-style-type: none"> - Incoming prescriptions for buprenorphine or buprenorphine/naloxone agents will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for any buprenorphine or buprenorphine/naloxone agent. - Incoming prescriptions for any naltrexone agent will deny when the recipient has an active prescription for any other naltrexone agent. 		
X – Prescribers of buprenorphine must meet enrollment and certification requirements.		

Opiate Dependence Agents

Revision / Date	Implementation Date
Created POS Document	February 2020
Updated age for BH in POS Abbreviations chart / November 2020	January 2021
Added POS edits for lofexidine and naltrexone / January 2021	April 2021
Modified quantity limit for Sublocade® / May 2022	June 2022
Modified wording for concurrent use with buprenorphine-containing products, Clarified DD for naltrexone / February 2022	July 2022
<u>Added Kloxxado™ and Zimhi™ and policy clarifications / April 2022</u>	<u>October 2022</u>